Literature DB >> 2424994

Identification of a chymotrypsin-like proteinase in human mast cells.

N M Schechter, J K Choi, D A Slavin, D T Deresienski, S Sayama, G Dong, R M Lavker, D Proud, G S Lazarus.   

Abstract

An antiserum was produced against a chymotryptic proteinase purified from human skin. The antiserum did not cross-react with human leukocyte cathepsin G and elastase, rat mast cell proteinase I, and human skin tryptase. Indirect immunofluorescent staining of frozen skin sections to localize the proteinase showed cytoplasmic staining of cells scattered about the papillary dermis and around blood vessels and appendages. Restaining these sections with toluidine blue revealed that the fluorescently stained cells contained metachromatically staining granules, the major distinguishing feature of mast cells. A similar correlation was found in lung tissue. Ultrastructural studies employing the ferritin bridge technique to immunologically identify the proteinase additionally localized the proteinase to mast cell granules. Biochemical and immunochemical characterization of chymotryptic activity solubilized from isolated human lung mast cells identified a chymotryptic proteinase that may be identical to the skin chymotryptic proteinase. These studies establish that human skin mast cells contain a chymotrypsin-like proteinase that is a granule constituent and provide evidence that indicates a comparable proteinase is also present in lung mast cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424994

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Chymase cleavage of stem cell factor yields a bioactive, soluble product.

Authors:  B J Longley; L Tyrrell; Y Ma; D A Williams; R Halaban; K Langley; H S Lu; N M Schechter
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 2.  Regulation and function of mast cell proteases in inflammation.

Authors:  C Huang; A Sali; R L Stevens
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

Review 3.  Mast cells, neuropeptides and inflammation.

Authors:  M K Church; M A Lowman; P H Rees; R C Benyon
Journal:  Agents Actions       Date:  1989-04

4.  The secretory characteristics of mast cells isolated from the human large intestinal mucosa and muscle.

Authors:  P H Rees; K Hillier; M K Church
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

5.  Evidence for in vivo degradation of C3a anaphylatoxin by mast cell chymase. I. Nonspecific activation of rat peritoneal mast cells by C3ades Arg.

Authors:  T Kajita; T E Hugli
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

6.  Isolation and characterization of trypsin-like and chymotrypsin-like proteinases from human cholesteatoma.

Authors:  K Hochstrasser; G J Albrecht; W Gebhard; G Rasp; E Kastenbauer
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

7.  Human mast cell carboxypeptidase. Purification and characterization.

Authors:  S M Goldstein; C E Kaempfer; J T Kealey; B U Wintroub
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

8.  Inactivation of thrombin by a complex between rat mast-cell protease 1 and heparin proteoglycan.

Authors:  G Pejler; K Söderström; A Karlström
Journal:  Biochem J       Date:  1994-04-15       Impact factor: 3.857

9.  Biochemical and immunological characterization of multiple glycoforms of mouse mast cell protease 1: comparison with an isolated murine serosal mast cell protease (MMCP-4).

Authors:  G F Newlands; D P Knox; S R Pirie-Shepherd; H R Miller
Journal:  Biochem J       Date:  1993-08-15       Impact factor: 3.857

10.  Interaction of human mast cell tryptase and chymase with low-molecular-mass serine proteinase inhibitors from the human respiratory tract.

Authors:  K Hochstrasser; W Gebhard; G Albrecht; G Rasp; E Kastenbauer
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.